Eprosartan does not affect the pharmacodynamics of warfarin

Journal of Clinical Pharmacology

Volumn 38, Issue 7, 1998, Pages 649-653

  Kazierad, David J ^a,d   Martin, David E ^a   Ilson, Bernard ^a   Boike, Steven ^a   Zariffa, Nevine ^c   Forrest, Alan ^b   Jorkasky, Diane K ^a  

^a PENN PRESBYTERIAN MEDICAL CENTER   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c SmithKline Beecham   (United States)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPROSARTAN; WARFARIN;

ADULT; ANTICOAGULATION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ELIMINATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; ENANTIOMER; HUMAN; HUMAN EXPERIMENT; MALE; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; VERTIGO;

EID: 0031903838     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1998.tb04473.x     Document Type: Article

References (17)

1. Goodfriend TL, Elliott ME, Catt KJ: Angiotensin receptors and their antagonists. N Engl J Med 1996;334:1649-1654.
2. Duncia JV, Chiu AT, Carini DJ, Gregory JB, Johnson AL, Price WA, et al: The discovery of potent non-peptide angiotensin II receptor antagonists: a new class of potent antihypertensives. J Med Chem 1990;33:1312-1329.
3. Brooks DP, Fredrickson TA, Weinstock J, Ruffolo RR, Edwards RM, Gellai M: Antihypertensive activity of the non-peptide angiotensin II receptor antagonist, SK&F 108566, in rats and dogs. Arch Pharmacol 1992;345:673-678.
4. Ilson B, Boike S, Freed, M, Everitt D, Brown L, Zariffa N, Jorkasky D: Renal hemodynamic effects of SK&F 108566, a non-peptide selective angiotensin (AII) receptor AT1 antagonist (abstract). Clin Pharmacol Ther 1994;55:206.
5. White WB, Mansoor GA, Lessem J, Shusterman N: Evaluation of the angiotensin II receptor antagonist, eprosartan, by casual and ambulatory BP monitoring (abstract). Clin Res 1994;42;447A.
6. Cox PJ, Bush BD, Gorycki PD, Kuo GY, Kenworthy D, Law DW, et al: The metabolic fate of eprosartan in healthy subjects. Exp Toxicol Pathol 1996;48:340-341.
7. Porter RS, Sawyer WT, Lowenthal DT: Warfarin. In, Evans WE, Schentag JJ, Jusko WJ (eds.): Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. Second edition. Spokane: Applied Therapeutics. 1986;1057-1104.
8. Hirsh J, Dalen JE, Deykin D, Poller L, Bussey H: Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1995;108(Suppl 4):231S-246S.
9. Wells PS, Holbrook AM, Crowther NR, Hirsh J: Interactions of warfarin with drugs and food. Ann Intern Med 1994;121:676-683.
10. MediFore, Inc.: DrugCalc Version 3.0. Lansing, MI:MediFore, Inc., 1991.
11. Wilkinson L: SYSTAT: The System for Statisics. Evanston, IL: SYSTAT, Inc., 1990.
12. Yamaoka K, Nakagawa T, Uno T: Application of Akaike's information criterion in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978;6:165-175.
13. White RH, Zhou H, Romano P, Mungall D: Changes in warfarin levels and variations in steady-state prothrombin times. Clin Pharmacol Ther 1995;58:588-593.
14. Kong AH, Tomasko L, Waldman SA, Osborne B, Deutsch PJ, Goldberg MR, Bjornsson TD: Losartan does not affect the pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol 1995;35:1008-1015.
15. Rocci ML, Vlasses PH, Distlerath LM, Gregg MH, Wheeler SC, Zing W, Bjornsson TD: Norfloxacin does not alter warfarin's disposition or anticoagulant effect. J Clin Pharmacol 1990;30:728-732.
16. Liao S, Palmer M, Fowler C, Nayak RK: Absence of an effect of levofloxacin on warfarin pharmacokinetics and anticoagulation in male volunteers. J Clin Pharmacol 1996;36:1072-1077.
17. Weiss P, Soff GA, Halkin H, Seligsohn U: Decline of proteins C and S and factors II, VII, IX and X during the initiation of warfarin therapy. Thromb Res 1987;45:783-790.